Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NewLimit is a biotechnology company pioneering epigenetic reprogramming to reverse cellular aging and treat age-related diseases. By combining machine learning, high-throughput biology, and CRISPR-based gene editing, we develop therapies that restore youthful function to aged cells. Founded by Blake Byers and Brian Armstrong, we aim to extend human healthspan through cutting-edge science. Our research focuses on unlocking the ...
NewLimit is a biotechnology company pioneering epigenetic reprogramming to reverse cellular aging and treat age-related diseases. By combining machine learning, high-throughput biology, and CRISPR-based gene editing, we develop therapies that restore youthful function to aged cells. Founded by Blake Byers and Brian Armstrong, we aim to extend human healthspan through cutting-edge science. Our research focuses on unlocking the potential of epigenetic reprogramming to combat degenerative diseases at their root cause.

List your booth number for exhibitions, ask us